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A 67-year-old Caucasian man presented with atrial flutter on routine 12-lead 
electrocardiography (ECG). Following appropriate anticoagulation, he successfully 
underwent atrial flutter ablation. Echocardiography during the admission showed concentric 
left ventricular (LV) hypertrophy with severely impaired LV systolic function, particularly 
longitudinal (Figure 1A, video 1), and biatrial dilatation. Due to episodes of non-sustained 
ventricular tachycardia, he was fitted with an implantable cardioverter-defibrillator (ICD). 
The ECG QRS complexes on peripheral leads were small compared to the structural wall 
thickening on echocardiography (Figure 1B) raising the suspicion of cardiac amyloidosis. 
Preliminary evaluation excluded a plasma cell dyscrasia (negative serum free light chains 
changes and urinary Bence-Jones protein). Serum amyloid P component (SAP) scintigraphy 
was negative for visceral organ uptake and bone tracer scintigraphy (Technetium-DPD) was 
positive with Perugini Grade 2-3 uptake (Figure 1C), consistent with a diagnosis of cardiac 
transthyretin amyloidosis (ATTR). Cardiac magnetic resonance (CMR) was contra-indicated 
due to the non-conditional ICD (Figure 1D). After giving fully informed written consent, 
cardiac computed tomography (CCT) was performed as part of a research study, using a three 
step protocol (Figure 1E) as previously described1, allowing calculation of the extracellular 
volume fraction (ECV) from pre- and 5-minutes post-contrast images. The septal ECV, 
calculated from a co-registered, segmented myocardial mask displaying pixel-by-pixel ECV 
values, was in the amyloid spectrum elevated at 63% (Figure 1F), Gene sequencing revealed 
a heterozygous V122I mutation, confirming the diagnosis of familial amyloid 
cardiomyopathy (ATTR). 
Discussion 
Quantification of the myocardial ECV using two-phase cardiac CT can discriminate between 
cardiac amyloidosis and other disease with myocardial hypertrophy. The ECV by CMR and 
CT strongly correlated, making CCT a valid alternative to CMR1, which itself is known to 
have good sensitivity and specificity for the diagnosis, prognostication and monitoring of 
cardiac amyloidosis2. Here, CCT added value as there was a MR non-conditional ICD in-situ.   
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